8-K – 2026-01-22 – d96058d8k.htm

8-K

CORCEPT THERAPEUTICS INC false 0001088856 0001088856 2026-01-22 2026-01-22
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 

FORM 8-K
 
 

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
January 22, 2026
Date of Report (date of earliest event reported)
 
 

Corcept Therapeutics Incorporated
(Exact name of registrant as specified in its charter)
 
 

 

Delaware
 
000-50679
 
77-0487658

(State or other jurisdiction
of incorporation)
 
(Commission
File Number)

 
(I.R.S. Employer
Identification No.)
101 Redwood Shores Parkway , Redwood City , CA 94065
(Address of Principal Executive Offices) (Zip Code)
(650) 327-3270
Registrant’s telephone number, including area code
Not Applicable
(Former name or former address, if changed since last report.)
 
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
 

Title of each class

 
Trading
Symbol(s)

 
Name of each exchange
on which registered

Common Stock, $0.001 par value
 
CORT
 
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 

Item 8.01.
Other Events.

On January 22, 2026, Corcept Therapeutics Incorporated (the “Company”) issued a press release announcing that ROSELLA, the Company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer, met its overall survival primary endpoint. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
 

Item 9.01.
Financial Statements and Exhibits

(d) Exhibits
 

Exhibits
No.

  
Description

99.1
  
Press Release of Corcept Therapeutics Incorporated, January 22, 2026

104.1
  
Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

 

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

 

 
CORCEPT THERAPEUTICS INCORPORATED

Date: January 22, 2026
 

 
By:
 
/s/ Atabak Mokari

 

 
Name:
 
Atabak Mokari

 

 
Title:
 
Chief Financial Officer